Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The 19 patients who experienced an ECG QT prolongation showed a mean prolongation of QT interval of 496.1 (SD ± 14.4) ms (Table 2).Case-by-case clinical description of all evaluated reportsCaseAge (years)M/FAdverse drug reactions (PT)OutcomeSuspected drugsConcomitant medicationsComorbidities136FNausea, vomiting, abdominal pain, drug level modificationImprovementTacrolimusDarunavir/cobicistatNoneRenal transplant280MECG QT prolonged, atrial flutter, hemiplegia, hypokalaemia, major depressionImprovementHCQRisperidoneSertraline, olanzapine, lorazepam, ceftriaxone, enoxaparin, lopinavir/ritonavir*, and darunavir/cobicistat*None361MHypertransaminasemiaImprovementLopinavir/ritonavirDarunavir/cobicistatTocilizumabHCQAzithromycin, bisoprolol, pantoprazole, enoxaparin, lorazepam, and atorvastatinAtrial fibrillation452FDiarrhoea, vomitingComplete resolutionDarunavir/cobicistatHCQAzithromycinNoneNone578FECG QT prolonged, hypokalaemiaImprovementHCQLopinavir/ritonavirDarunavir/cobicistat*Cardiomyopathy and pacemaker684MECG QT prolonged, vomitingImprovementHCQLopinavir/ritonavirAzithromycinNonePancreatic lesions756MECG QT prolongedImprovementHCQLopinavir/ritonavirAzithromycinDarunavir/cobicistat*, enoxaparin, acetylsalicylic acid, candesartan, losartan, betamethasone, and amoxicillinHypertension893FECG QT prolongedImprovementHCQCitalopramSimvastatin, levothyroxine, bromazepam, trazodone, enoxaparin, azithromycin, ceftriaxoneNone982FECG QT prolongedImprovementHCQLopinavir/ritonavirAzithromycinSevelamer, pantoprazole, bisoprolol, furosemide, methylprednisolone, piperacillin/tazobactam, linezolid, and epoetin alphaRenal failure, anaemia, hypertension1080MECG QT prolongedUnchanged eventHCQSertralineAzithromycinValsartan, esomeprazole, pantoprazole, lorazepam, amlodipine, mesalamine, tamsulosin, loperamide, piperacillin/tazobactam, acetylsalicylic acid, enoxaparin, and furosemideNone1167FECG QT prolongedUnchanged eventHCQLopinavir/ritonavirAzithromycinHaloperidolLevomepromazineZuclopenthixolValproic acid, atorvastatin, lorazepam, and fondaparinuxParanoid schizophrenia, hypercholesterolemia1285MECG QT prolongedUnchanged eventLopinavir/ritonavirHCQPiperacillin/tazobactam, magnesium sulphate, linezolid, fluticasone propionate/vilanterol, bisoprolol, pantoprazole, thiamazole, allopurinol, acetylsalicylic acid, ursodeoxycholic acid, calcium carbonate, and calcitriolRenal failure, hyperthyroidism, BPH, heart failure1370FECG QT prolongedDeathHCQDarunavir/cobicistatAzithromycinAmiodaroneWarfarin, furosemide, potassium chloride, atorvastatin, amoxicillin/clavulanate, acetaminophen, enoxaparin, ruxolitinib, and aclidinium bromideCOPD, hypothyroidism, atrial fibrillation, renal failure1486MECG QT prolongedImprovementHCQLopinavir/ritonavirFurosemide, apixaban, atorvastatin,nitroglycerine, clonidine, potassium chloride, darunavir/cobicistat*, and enoxaparinNone1593MECG QT prolongedDeathLopinavir/ritonavirHCQAzithromycinCeftriaxone, furosemide, bisoprolol, tamsulosin, dutasteride, ramipril, enoxaparin, insulin, gliclazide, vildagliptin, metformin, perindopril, barnidipine, and simvastatinDiabetes, hypertension, BPH, vascular encephalopathy, lower limbs obliterating arteriopathy1680MECG QT prolongedDeathLopinavir/ritonavirHCQAzithromycinHaloperidolVerapamil, lansoprazole, acetylsalicylic acid, macrogol, and enoxaparinAlzheimer and Parkinson’s diseases, hypertension, right carotid stenosis, renal failure, hepatic steatosis1785MECG QT prolonged, hypokalaemiaImprovementHCQMagnesium sulphateTamsulosin, bisoprolol, warfarin, atorvastatin, bicalutamide, rabeprazole, meropenem, vancomycin, and potassium chlorideHypertension, hypercholesterolemia, neuropathic pain, prostatic cancer, mitral valve intervention, hypokalaemia and hypomagnesemia1871MECG QT prolongedImprovementHCQDarunavir/cobicistatSimvastatin, allopurinol, olmesartan, nebivolol, rivaroxaban, and potassium chlorideHypertension, dyslipidaemia, atrial fibrillation, pulmonary emphysema, obesity1989MECG QT prolongedInitial improvement of QT prolongation and deathLopinavir/ritonavirHCQAzithromycinCitalopramPantoprazole, bisoprolol, clopidogrel, atorvastatin, quetiapine, promazine, piperacilline/tazobactam, enoxaparin, and olanzapineMild mental retardation, Parkinson's disease, past severe head injury with subdural hematoma, chronic dysphagia, thrombocytopenia, anaemia, hypertension, dyslipidaemia, chronic renal failure2065MPsychosis, agitation, delirium, aggressivenessImprovementHCQDarunavir/cobicistatTocilizumabDutasteride, allopurinol, propofol, risperidone, valproic acid, clonazepam, ramipril, amlodipine, midazolam, spironolactone, dexmedetomidine, and olanzapineOverweight, hyperuricemia, prostatic hypertrophy2181FECG QT prolongedImprovementHCQDarunavir/cobicistatThiamazole, pantoprazole, folic acid, potassium chloride, bisoprolol, furosemide, warfarin, potassium canrenoate, alprazolam, enoxaparin and iron, vitamin C and vitamin B12 supplementationAtrial fibrillation, hypertension, hyperthyroidism, osteoporosis, mitral valve disease2289FECG QT prolongedDeathHCQTrazodoneCeftriaxone, methylprednisolone, acetylsalicylic acid, acetaminophen/codeine, alprazolam, omeprazole, valproic acid, morphine, enoxaparin, calcium and vitamin D3 supplementationCognitive impairment, chronic subcortical vascular encephalopathy, kidney heteroplasia, hypertension, osteoporosis, osteoarthritis, anxiety-depressive syndrome2388FECG QT prolongedImprovementHCQDarunavir/cobicistatHaloperidolPromazine, enoxaparin, and potassium chlorideAlzheimer’s diseaseBPH benign prostatic hyperplasia, COPD chronic obstructive pulmonary disease, ECG electrocardiogram, F female, HCQ hydroxychloroquine, M male*This medication was not administered simultaneously with the suspected drugs.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In the present observational study, we considered and evaluated all reports of suspected ADRs collected in the COVID-19 Units of Careggi University Hospital, Florence (Italy), between January 1st and 31st May, 2020.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions

Observational study · Internal and Emergency Medicine · 2020

Original publication title

Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug: drug interactions

Giada Crescioli; Valentina Brilli; Cecilia Lanzi; Andrea Burgalassi; Alessandra Ieri; Roberto Bonaiuti; Elias Romano; Rinaldo Innocenti; Guido Mannaioni; Alfredo Vannacci; Niccolò Lombardi

© The Author(s) 2020

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Due to the need of early and emergency effective treatments for COVID-19, less attention may have been paid to their safety during the global emergency. In addition, characteristics of drug: drug interaction (DDI)-related adverse drug reactions (ADRs) in COVID-19 patients have not yet been studied in depth. The aim of the present case-series study is to describe clinical and pharmacological characteristics of SARS-CoV-2 hospitalised patients, focusing on ADRs, particularly those related to DDIs. We evaluated all reports of COVID-19 medication-related ADRs collected within the COVID-19 Units of Careggi University Hospital, Florence (Italy), between January 1st and 31st May 2020.

Information regarding COVID-19 medications, patients’ demographic and clinical characteristics, concomitant drugs, ADRs description and outcome, were collected. Each case was evaluated for the causality assessment and to identify the presence of DDIs. During the study period, 23 Caucasian patients (56.5% males, mean age 76.1 years) experienced one or more ADRs. The majority of them were exposed to polypharmacy and 17.4% presented comorbidities. ADRs were referred to cardiovascular, psychiatric and gastrointestinal disorders. The most frequently reported preferred term was QT prolongation (mean QT interval 496.1 ms).

ADRs improved or resolved completely in 60.8% of cases. For all patients, a case-by-case evaluation revealed the presence of one or more DDIs, especially those related to pharmacokinetic interactions. Despite the small number of patients, our evidence underline the clinical burden of DDIs in SARS-CoV-2 hospitalised patients and the risk of unexpected and uncommon psychiatric ADRs.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11739-020-02586-8.

Authors’ abstract

Due to the need of early and emergency effective treatments for COVID-19, less attention may have been paid to their safety during the global emergency. In addition, characteristics of drug: drug interaction (DDI)-related adverse drug reactions (ADRs) in COVID-19 patients have not yet been studied in depth. The aim of the present case-series study is to describe clinical and pharmacological characteristics of SARS-CoV-2 hospitalised patients, focusing on ADRs, particularly those related to DDIs. We evaluated all reports of COVID-19 medication-related ADRs collected within the COVID-19 Units of Careggi University Hospital, Florence (Italy), between January 1st and 31st May 2020.

Information regarding COVID-19 medications, patients’ demographic and clinical characteristics, concomitant drugs, ADRs description and outcome, were collected. Each case was evaluated for the causality assessment and to identify the presence of DDIs. During the study period, 23 Caucasian patients (56.5% males, mean age 76.1 years) experienced one or more ADRs. The majority of them were exposed to polypharmacy and 17.4% presented comorbidities. ADRs were referred to cardiovascular, psychiatric and gastrointestinal disorders. The most frequently reported preferred term was QT prolongation (mean QT interval 496.1 ms).

ADRs improved or resolved completely in 60.8% of cases. For all patients, a case-by-case evaluation revealed the presence of one or more DDIs, especially those related to pharmacokinetic interactions. Despite the small number of patients, our evidence underline the clinical burden of DDIs in SARS-CoV-2 hospitalised patients and the risk of unexpected and uncommon psychiatric ADRs.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11739-020-02586-8.

Publication and source details

Original title: Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug: drug interactions

Giada Crescioli; Valentina Brilli; Cecilia Lanzi; Andrea Burgalassi; Alessandra Ieri; Roberto Bonaiuti; Elias Romano; Rinaldo Innocenti; Guido Mannaioni; Alfredo Vannacci; Niccolò Lombardi

Internal and Emergency Medicine · 2020

© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Firenze

Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:49:20.399854+00:00

DOI: 10.1007/s11739-020-02586-8 · PMC7755981